Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …

Background Assessing safety and efficacy of Covid-19 vaccines in different populations is
essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern …

Background Tuberculosis is a major public health problem worldwide. Immunisation with
Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of …

Background Limitations in laboratory testing capacity undermine the ability to quantify the
overall burden of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. …

Background Pneumococcal conjugate vaccine (PCV) immunisation has reduced vaccine-serotype
colonisation and invasive pneumococcal disease in South Africa, providing the …

Background Routine childhood immunisation with pneumococcal conjugate vaccine (PCV)
has changed the epidemiology of pneumococcal disease across age groups, providing an …

Background Licensure of a group B Streptococcus (GBS) polysaccharide-protein conjugate
vaccine for protecting infants against invasive GBS disease (IGbsD) will likely need to be …

Background Standard-dose, seasonal, trivalent, inactivated influenza vaccine induces
moderate-to-low haemagglutination-inhibition antibody responses in people living with HIV. This …

Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern
1. People living with HIV (PLWH) are at increased risk for adverse COVID-19 outcomes …